OraSure Technologies (OSUR) Scheduled to Post Earnings on Wednesday

OraSure Technologies (NASDAQ:OSUR) will be issuing its quarterly earnings data after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.04 per share for the quarter. OraSure Technologies has set its Q1 2024 guidance at EPS.Investors that wish to listen to the company’s conference call can do so using this link.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.09. OraSure Technologies had a net margin of 13.23% and a return on equity of 14.50%. The business had revenue of $75.88 million during the quarter, compared to analyst estimates of $74.13 million. During the same period in the previous year, the business earned $0.21 EPS. OraSure Technologies’s revenue was down 38.3% compared to the same quarter last year. On average, analysts expect OraSure Technologies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

OraSure Technologies Price Performance

OraSure Technologies stock opened at $5.50 on Tuesday. OraSure Technologies has a one year low of $4.38 and a one year high of $8.45. The firm has a market capitalization of $420.81 million, a P/E ratio of 7.64 and a beta of 0.23. The business has a fifty day moving average price of $6.15 and a 200-day moving average price of $6.81.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on OSUR. StockNews.com upgraded OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Wednesday, May 1st. Evercore ISI cut their price target on shares of OraSure Technologies from $7.00 to $6.50 and set an “in-line” rating for the company in a report on Thursday, April 4th. Two analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $6.38.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.